JUL 30, 2020 12:49 PM PDT

Protecting the Heart Against Cardiotoxicity

WRITTEN BY: Jasper Cantrell

Doxorubicin is a potent chemotherapy drug used for many different cancers. Unfortunately, like all chemotherapies, doxorubicin suffers from a measure of toxicity. The toxicity can progressively weaken the heart, which, if not treated, will eventually cause heart failure.

Scientists are researching several areas to prevent the toxic side effects of many chemotherapy drugs. For doxorubicin, the microRNA miR-34a presents a possible solution. MicroRNAs are small regulatory molecules that can bind to genetic products and silence them. MiR-34a is a regulator of cardiac repair and was present at higher levels in doxorubicin treated tissues.  

A team from the University of Campania in Italy wanted to study how an inhibitor targeting miR-34a would impact cardiotoxicity in doxorubicin treated rats. Their previous work had shown that a miR-34a inhibitor could suppress miR-34a activity and promote pro-survival pathways in heart cells. This new study sought to test this in animals.

They used the same miR-34a inhibitor from their previous study to treat rats four weeks after a two-week doxorubicin treatment. They checked each rat’s heart health at three and six weeks and found that the miR-34a inhibitor improved heart function compared to control doxorubicin groups. Heart function was comparable to control rats who hadn’t received any treatment, inferring the inhibitor may completely stop the cardiotoxicity.

The study moved forward and investigated the mechanism behind how the miR-34a inhibitor worked as a protective agent. They found that the inhibitor suppressed apoptotic (programmed cell death) pathways and promoted cell survival pathways in cells with or without doxorubicin treatment. It even prevented cardiac fibrosis and inflammation, both of which impact cardiovascular health.

The miR-34a inhibitor tested in this study clearly protects animals in the study from doxorubicin’s cardiotoxic side effects. The protection may even spread to other organs, as the inhibitor was found throughout the animals. There is an issue of not knowing how it affects doxorubicin’s anti-cancer activity. The team notes that their previous in vitro study showed that it took a significant amount of the inhibitor to see any reduction in doxorubicin’s activity.

The study concludes, “our data demonstrate that systemic inhibition of miR-34a offers a promising therapeutic approach in DOXO-induced toxicity since mediates cardioprotective pleiotropic beneficial effects”.

Sources: Nature Scientific Reports, British Heart Foundation

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 05, 2020
Cannabis Sciences
Cannabis Might Trigger Heart Problems Says AHA
AUG 05, 2020
Cannabis Might Trigger Heart Problems Says AHA
The American Heart Association (AHA) has produced a new statement about medical marijuana and recreational cannabis. The ...
AUG 15, 2020
Cardiology
Following Platelets to Diagnose Myocarditis
AUG 15, 2020
Following Platelets to Diagnose Myocarditis
The heart is a sensitive thing, prone not just to metaphorical heartbreak, but genuine issues if not taken care of. Myoc ...
SEP 15, 2020
Cardiology
Dopamine Could Cause Heart Arrhythmia After Heart Failure
SEP 15, 2020
Dopamine Could Cause Heart Arrhythmia After Heart Failure
Everyone knows that friend with a tattoo of a molecule of dopamine. Usually associated with the pleasure response, it is ...
SEP 18, 2020
Clinical & Molecular DX
Open Your Heart to the World's Smallest Diagnostic Probe
SEP 18, 2020
Open Your Heart to the World's Smallest Diagnostic Probe
Certain health conditions require doctors to be able to observe tissues and organs in order to tell what’s wrong. ...
OCT 14, 2020
Immunology
Happiness Linked to Heart Attack Risk
OCT 14, 2020
Happiness Linked to Heart Attack Risk
Asking patients questions about their personal lives could predict their future risk of a heart attack. A study, publish ...
NOV 24, 2020
Cardiology
Patients on Statins Get the 'Nocebo Effect'
NOV 24, 2020
Patients on Statins Get the 'Nocebo Effect'
Millions of people around the world take statins to treat high cholesterol, which are estimated to reduce the risk of he ...
Loading Comments...